Toyonaga Y, Kurosu Y, Nakamura H, Sugita M, Takahashi T, Hori M
Jpn J Antibiot. 1984 Dec;37(12):2457-77.
Sulbactam (SBT) in a novel beta-lactamase inhibitor from Pfizer and combined with cefoperazone (CPZ) ina 1:1 ratio (SBT/CPZ). Fundamental and clinical studies on SBT/CPZ were executed. The antibacterial activity of SBT/CPZ was compared with those of SBT, CPZ and CEZ against clinical isolates of S. aureus and E. coli which were not susceptible to CEZ. SBT alone did not show any activity against S. aureus, MICs against all strains were over than 100 micrograms/ml on the inoculations of undiluted and 100-fold diluted specimen. CPZ showed MICs over than 100 micrograms/ml against approximately 70% of the isolates on the undiluted inoculation, and on the 100-fold diluted inoculation, the MIC50 and MIC70 were 12.5 micrograms/ml and 100 micrograms/ml, respectively. SBT/CPZ showed better activity than CPZ by 2-8 folds against the strains highly resistant to CPZ; the MIC50 on the undiluted inoculation was 50 micrograms/ml. Against E. coli, the characteristic of SBT/CPZ was shown more clearly. The MICs of CPZ were over than 100 micrograms/ml against approximately 70% of the isolates on the undiluted inoculation, but SBT/CPZ showed MIC50 at 25 micrograms/ml. On the 100-fold diluted inoculation, SBT/CPZ was 4 approximately 8-fold superior than CPZ against strains on which MICs of CPZ were over than 12.5 micrograms/ml. Serum levels were determined by a bolus intravenous injection and by intravenous drip infusion of 10, 20, 40 mg/kg of SBT/CPZ. When administered by a bolus injection, the peak level was seen at 30 minutes in most patients: 8.7, 14.7 or 27.0 micrograms/ml of SBT and 30.1, 42.5 or 76.4 micrograms/ml of CPZ were detected with the 3 different doses. These levels were dose-dependent, and decreased slowly to 0.3, 0.3 or 0.3 micrograms/ml of SBT and 2.9, 2.8 or 3.3 micrograms/ml of CPZ at 6 hours after administration. Half-lives were 1.39, 1.20 or 0.98 hour for SBT and 1.77, 1.59 or 1.42 hours for CPZ. The same 3 doses were given by intravenous drip infusion. The peak levels obtained at the end of infusion (1 hour after initiation of infusion) were 15.3, 14.4 or 43.2 micrograms/ml for SBT and 33.4, 38.2 or 104.2 micrograms/ml for CPZ, respectively. The levels were somewhat low in 20 mg/kg group. After the end of infusion, these levels decreased fairly rapidly, and after 6 hours almost the same levels of 0.4, 0.5 or 0.3 micrograms/ml for SBT and 1.4, 3.9 or 3.3 micrograms/ml for CPZ were detected.(ABSTRACT TRUNCATED AT 400 WORDS)
舒巴坦(SBT)是辉瑞公司研发的一种新型β-内酰胺酶抑制剂,与头孢哌酮(CPZ)以1:1的比例(SBT/CPZ)联合使用。对SBT/CPZ进行了基础和临床研究。将SBT/CPZ对金黄色葡萄球菌和大肠杆菌临床分离株的抗菌活性与SBT、CPZ和头孢唑啉(CEZ)进行了比较,这些分离株对CEZ不敏感。单独使用SBT对金黄色葡萄球菌没有任何活性,在未稀释和100倍稀释标本接种时,对所有菌株的最低抑菌浓度(MIC)均超过100微克/毫升。CPZ在未稀释接种时,对约70%的分离株的MIC超过100微克/毫升,在100倍稀释接种时,MIC50和MIC70分别为12.5微克/毫升和100微克/毫升。SBT/CPZ对高度耐CPZ的菌株的活性比CPZ高2至8倍;未稀释接种时的MIC50为50微克/毫升。对大肠杆菌而言,SBT/CPZ的特性表现得更为明显。CPZ在未稀释接种时,对约70%的分离株的MIC超过100微克/毫升,但SBT/CPZ的MIC50为25微克/毫升。在100倍稀释接种时,对于CPZ的MIC超过12.5微克/毫升的菌株,SBT/CPZ比CPZ约强4至8倍。通过静脉推注和静脉滴注10、20、40毫克/千克的SBT/CPZ来测定血清水平。静脉推注给药时,大多数患者在30分钟时出现峰值水平:3种不同剂量下分别检测到SBT为8.7、14.7或27.0微克/毫升,CPZ为30.1、42.5或76.4微克/毫升。这些水平呈剂量依赖性,给药6小时后缓慢降至SBT为0.3、0.3或0.3微克/毫升,CPZ为2.9、2.8或3.3微克/毫升。SBT的半衰期分别为1.39、1.20或0.98小时,CPZ的半衰期分别为1.77、1.59或1.42小时。通过静脉滴注给予相同的3种剂量。滴注结束时(滴注开始后1小时)获得的峰值水平,SBT分别为15.3、14.4或43.2微克/毫升,CPZ分别为33.4、38.2或104.2微克/毫升。20毫克/千克组的水平略低。滴注结束后,这些水平下降相当迅速,6小时后检测到SBT几乎相同的水平为0.4、0.5或0.3微克/毫升,CPZ为1.4、3.9或3.3微克/毫升。(摘要截取自400字)